<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986322</url>
  </required_header>
  <id_info>
    <org_study_id>Penta 0211</org_study_id>
    <nct_id>NCT01986322</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine</brief_title>
  <official_title>Phase 2 Study of Immunogenicity and Safety of DPT/HB/Hib (Bio Farma) Vaccine Compared to DTP/HB (Bio Farma) Vaccine Given Simultaneously With Hib (Registered) Vaccine in Indonesian Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study was to evaluate the protectivity and safety of DTP/HB/Hib
      (Bio Farma) vaccine compared to DTP/HB and Hib vaccine given simultaneously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial was randomized, single blind, prospective intervention study. Total 220 subject
      (6-11 weeks of ages) followed this trial, divided into 2 groups, each group consists of 110
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protectivity of DTP/HB/Hib (Bio Farma) vaccine</measure>
    <time_frame>4 months</time_frame>
    <description>Percentage of infants with anti diphteria titer and anti tetanus titer &gt;= 0.01 IU/ml, AntiHbs titer &gt;=10mlIU/ml, and antiPRP-TT titer &gt;= 0,15ug/ml 28 days after the last injection (third) in DPT/HB/Hib liquid vaccine group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response to diphteria toxoid in both group</measure>
    <time_frame>4 months</time_frame>
    <description>Serological response to diphteria toxoid: GMT, percentage of infants with titer &gt;=0.01 IU/ml and &gt;=0.1 IU/ml, percentage of infants with increasing antibody titer &gt;=4 times and/or percentage of infants with transition of seronegative to seropositive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response to Tetanus Toxoid in both group</measure>
    <time_frame>4 months</time_frame>
    <description>Serological response to tetanus toxoid: GMT, percentage of infants with titer &gt;=0.01 IU/ml and &gt;=0.1 IU/ml, percentage of infants with increasing antibody titer &gt;=4 times and/or percentage of infants with transition of seronegative to seropositive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response to Pertussis component in both group</measure>
    <time_frame>4 months</time_frame>
    <description>Serological response to the pertussis component (agglutinins): GMT,percentage of infants with titre &gt;=40, &gt;=80,&gt;=160 and &gt;=320 (1/dil.), percentage of infants with increasing antibody titer &gt;=4 times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response to Hepatitis B in both group</measure>
    <time_frame>4 months</time_frame>
    <description>Serological response to Hepatitis B: Geometric mean of anti-HBs, percentage of infants with titer &gt;=10mlIU/ml, percentage of infants with increasing antibody titer &gt;=4 times and/ or percentage of infants with transition of seronegative to seropositive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response to PRP-T in both group</measure>
    <time_frame>4 months</time_frame>
    <description>Serological response to Hib/PRP: GMT, percentage of infants with titre &gt;=1ug/ml and &gt;=0.15ug/ml, percentage of infants with increasing antibody titer &gt;=4 times and/or percentage of infants with transition of seronegative to seropositive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of adverse event of DTP/Hepatitis B/Hib vaccine (Bio Farma)</measure>
    <time_frame>30 minutes, 72 hours, 28 days after immunization</time_frame>
    <description>Local and systemic reaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DTP/HB/Hib vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.
DTP/HB/Hib component:
Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTP/HB and Hib vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age
DTP/HB component:
Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal
Hib component:
Purified Haemophilus influenzae type b polysaccharide 10 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTP/HB/Hib vaccine</intervention_name>
    <description>Dosage equal to 0.5 mL administered intramuscularly</description>
    <arm_group_label>DTP/HB/Hib vaccine</arm_group_label>
    <other_name>Pentavalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTP/HB and Hib vaccine</intervention_name>
    <description>Dosage equal to 0.5 mL administered intramuscularly</description>
    <arm_group_label>DTP/HB and Hib vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infant 6-11 week of age

          -  Infant born after 37-42 week of pregnancy

          -  Infant weighing more than 2.5 kg at birth

          -  Father, mother or legally acceptable representative properly informed about the study
             and having signed the informed consent form

          -  Parents commit themselves to comply with the indication of the investigator and with
             the schedule of the trial

          -  Mother at least graduate from elementary school

          -  Received Hepatitis B vaccine (Bio Farma) at birth

        Exclusion Criteria:

          -  Child concomitantly enroll or schedule to be enroll in another trial

          -  Evolving moderate or severe illness, especially infectious diseases or fever (axillary
             temperature &gt;=37.5 Celsius on Day 0)

          -  Known history of allergy to any component of the vaccine component (e.g.formaldehyde)

          -  History of uncontrolled coagulopathy or blood disorder contraindicating intramuscular
             injection

          -  Known history of congenital or acquired immunodeficiency (including HIV infection)

          -  Child who has received in the previous 4 weeks a treatment likely to alter the immune
             response (intravenous immunoglobulin, blood derived product or long term
             corticotherapy (&gt;2 weeks)

          -  Other vaccination within the 7 days prior to inclusion with the exception of BCG and
             poliomyelitis

          -  Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objective

          -  Infant with a known history of diphteria, tetanus, pertussis, Hib, Hepatitis B
             infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>11 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kusnandi Rusmil, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine UNPAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Garuda Primary Health Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibrahim Adji Primary Health Care Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puter Primary Health Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>November 11, 2013</last_update_submitted>
  <last_update_submitted_qc>November 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DTP/HB/Hib vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Infants</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

